To identify the miR-216a-3p levels responsible for sorafenib unresponsiveness, we performed a clinical analysis in a set of pre-treated tumor tissues from 20 patients randomly, the IHC scores showed miR-216-3p expression negatively correlated with MAPK14 protein levels in clinical HCC and adjacent normal liver tissues (n=20, p=0.017; Figure 1D). Here, MAPK14 is linked to neoplasm.